Bupropion controlled-release - IntelGenx

Drug Profile

Bupropion controlled-release - IntelGenx

Alternative Names: Bupropion extended-release; CPI-300; Forfivo XL; INT 0004/2006

Latest Information Update: 06 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cary Pharmaceuticals; IntelGenx Corp.
  • Developer IntelGenx Corp.
  • Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Major depressive disorder

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 02 Dec 2014 IntelGenx extends license agreement with Edgemont Pharmaceuticals for the commercialisation of bupropion controlled-release in USA
  • 27 Nov 2014 Bupropion controlled-release - IntelGenx is available for licensing in (excluding USA) as of 27 Nov 2014. http://www.intelgenx.com
  • 28 Aug 2013 Wockhardt Bio AG advises IntelGenx of an ANDA submission to manufacture and market generic versions of Fortivo® XL 450mg capsules in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top